Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Vantia Therapeutics announced the appointment of Rachel Morten as Head of regulatory affairs.
Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma, a regulatory consultancy that was acquired by Hesperion in 2004.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.